ArticleCancer cell2010
RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.
Article in Cancer cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 234 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
234 citing papers in PubMed, 1 synthesis or guideline pooled it, 443 citations in OpenAlex.
- Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2016Pooled it
- Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.Blood cancer journal · 2017Trial
- Current updates regarding biogenesis, functions and dysregulation of microRNAs in cancer: Innovative approaches for detection using CRISPR/Cas13‑based platforms (Review).International journal of molecular medicine · 2025Review
- Hsa-miR-194-5p and hsa-miR-195-5p are down-regulated expressed in high dysplasia HPV-positive Pap smear samples compared to normal cytology HPV-positive Pap smear samples.BMC infectious diseases · 2024Article
- The Analysis of Selected miRNAs and TargetBiomedicines · 2023Article
- Identification of hub genes and microRNAs with prognostic values in esophageal cancer by integrated analysis.Non-coding RNA research · 2023Article
- Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression.Journal of experimental & clinical cancer research : CR · 2023Article
- Accumulation of DNA damage alters microRNA gene transcription in Arabidopsis thaliana.BMC plant biology · 2022Article
- Review
- MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.Molecular medicine (Cambridge, Mass.) · 2022Review
- Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.Molecular biology reports · 2022Review
- MicroRNA-101-3p Suppresses Cancer Cell Growth by Inhibiting the USP47-Induced Deubiquitination of RPL11.Cancers · 2022Article
- MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.Thoracic cancer · 2022Article
- Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples.EBioMedicine · 2022Article
- Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis.Cancers · 2022Review
- Analysis of the p53/microRNA Network in Cancer.Advances in experimental medicine and biology · 2022Review
- Roles of miRNA dysregulation in the pathogenesis of multiple myeloma.Cancer gene therapy · 2021Review
- Review
- Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Reduction of lamin B receptor levels by miR-340-5p disrupts chromatin, promotes cell senescence and enhances senolysis.Nucleic acids research · 2021Article
174 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2022-10-27Falsification/Fabrication of Image · Investigation by Company/Institution · Upgrade/Update of Prior Notice(s) · · retraction for correction separately indexed in PMID: 36306791 DOI: 10.1016/j.ccell.2022.10.007
- Correction · 2016-08-08Duplication of/in Image · Error in Image · Updated to Retraction ·
- Commented on by
- Erratum issued
- Retracted
Authors and funding
19 authors at 7 institutions in 4 countries.
Funding
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the editors. This article was published on October 19, 2010, and Figures 4A and 7A were later corrected on August 8, 2016. In January 2021, The Ohio State University notified the Cancer Cell editors that an internal investigation concluded that Figures 1E, 4A, 4D, 5A, and 7A were falsified and that part of Figure 1E of the article is the same as part of Figure 1F in the correction of another article (Pichiorri et al., 2017, J. Exp. Med., 214, 1557, https://doi.org/10.1084/jem.2012095001172017c) and recommended retraction of the article. The editors no longer have confidence in the validity of the data and are retracting the article. S.-S. S. agrees with the retraction, and F.P., C.H., A.P., and C.M.C. disagree with the retraction; all other authors couldn't be reached or didn't respond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.